Aligning Patients’ and Clinicians’ Outcomes Expectations in Ulcerative Colitis Management: Modulation of Lymphocyte Migration and Patient-Centered Outcomes
Speakers: William J. Sandborn, MD, Professor of MedicineVipul Jairath, MBChB, DPhil, MRCP, FRCPC, Professor of Medicine
Duration: 60 minutes
Presented on: August 4, 2021
Aligning Patients’ and Clinicians’ Outcomes Expectations in Ulcerative Colitis Management Modulation of Lymphocyte Migration and Patient-Centered Outcomes
LEARNING OBJECTIVESAt the conclusion of this activity, participants will be able to:
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with the Crohn's and Colitis Foundation (CCF).
- Identify areas of miscommunication and engage patients on management expectations for UC, including the definition and achievement of remission
- Describe the role of sphingosine-1-phosphate (S1P) signaling molecules in the pathophysiology of inflammatory bowel disease (IBD) and UC
- Summarize clinical data on the use of specific oral S1P receptor modulators to induce and maintain remission in patients who are naïve or experienced with anti-TNF agents
- Discuss the potential place of S1P receptor modulators in the care of patients with UC
This activity is supported by an educational grant from Bristol-Myers Squibb (BMS).
JOINT ACCREDITATION STATEMENTIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
LIVE CREDIT DESIGNATION STATEMENTThe Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. In addition, through an agreement between the Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
ENDURING CREDIT DESIGNATION STATEMENTThe Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. In addition, through an agreement between the Accreditation Council for Continuing Medical Education (ACCME) and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
DATE OF RELEASE/EXPIRATION
Live ActivityWednesday, August 4, 2021 at 4:00 - 5:00pm EST
Enduring MaterialAugust 4, 2021 - August 4, 2022.
TARGET AUDIENCEThe intended audience for this activity program are gastroenterologists, primary care physicians, physician assistants, nurse practitioners, pharmacists, and allied healthcare professionals involved in the management of patients with IBD.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
METHOD OF PARTICIPATIONThere are no fees to participate in this activity. To participate in the activity, go to www.ImmunologyLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTERESTPostgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship William J. Sandborn, MD
Professor of Medicine
Division of Gastroenterology
University of California San Diego
Salary: Shoreline Biosciences
Consulting Fees (e.g., advisory boards): Abbvie, Abivax, Admirx, Alfasigma, Alimentiv (previously Robarts Clinical Trials, owned by Alimentiv Health Trust), Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport, Arena Pharmaceuticals, Bausch Health (Salix), Beigene, Bellatrix Pharmaceuticals, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Meyers Squibb, Celgene, Celltrion, Cellularity, Cosmo Pharmaceuticals, Escalier Biosciences, Equillium, Forbion, Genentech/Roche, Gilead Sciences, Glenmark Pharmaceuticals, Gossamer Bio, Immunic (Vital Therapies), Index Pharmaceuticals, Intact Therapeutics, Janssen, Kyverna Therapeutics, Landos Biopharma, Lilly, Oppilan Pharma (acquired by Ventyx Biosciences), Otsuka, Pandion Therapeutics, Pfizer, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonists Therapeutics, Provention Bio, Reistone Biopharma, Seres Therapeutics, Shanghai Pharma Biotherapeutics, Shire, Shoreline Biosciences, Sublimity Therapeutics, Surrozen, Takeda, Theravance Biopharma, Thetis Pharmaceuticals, Tillotts Pharma, UCB, Vendata Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivelix Pharmaceuticals, Vivreon Biosciences, Zealand Pharma
Contracted Research: Abbvie, Abivax, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene, Genentech, Gilead Sciences, Glaxo Smith Kline, Janssen, Lilly, Pfizer, Prometheus Biosciences, Seres Therapeutics, Shire, Takeda, Theravance Biopharma
Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds): Allakos, BeiGene, Gossamer Bio, Oppilan Pharma (acquired by Ventyx Biosciences), Prometheus Biosciences, Prometheus Laboratories Progenity, Shoreline Biosciences, Ventyx Biosciences, Vimalan Biosciences, Vivreon Biosciences
Other: Iveric Bio - consultant, stock options; Progenity - stock; Oppilan Pharma (acquired by Ventyx Biosciences) - consultant, stock options; Prometheus Biosciences - employee, stock, stock options; Prometheus Laboratories – stock, stock options )
Vipul Jairath, MBChB, DPhil, MRCP, FRCPC
Professor of Medicine
John and Susan McDonald Endowed Chair in Inflammatory Bowel Disease Clinical Research
Division of Gastroenterology
Western University & London Health Sciences Centre
University Hospital, London, ON, Canada
Consulting Fees (e.g., advisory boards):strong> AbbVie, Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), Amgen, Applied Strategic, Arena Pharmaceuticals, Asieris, Celgene/BMS, Celltrion, Eli Lilly, Ferring, F. Hoffman-La Roche Ltd., Fresenius Kabi, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Organon (Merck), Mylan, Pandion, Pendopharm, Pfizer, Reistone Biopharma, Sandoz, Takeda, Topivert
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Carole Drexel
PlatformQ Health Education, LLC
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATIONAccreditation Support: Please contact the Postgraduate Institute for Medicine at firstname.lastname@example.org.
Technical Support: For any technical issues or issues with your CME Certificate, please contact ImmunologyLive.com at 877-394-1306 or at Support@ImmunologyLive.com.